Ras regulates SCFβ-TrCP protein activity and specificity via its effector protein NORE1A

Journal of Biological Chemistry

Volumn 289, Issue 45, 2014, Pages 31102-31110

  Schmidt, M Lee ^a   Donninger, Howard ^b   Clark, Geoffrey J ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ACTIVITY;

BETA CATENIN; CARRIER PROTEINS AND BINDING PROTEINS; I KAPPA B; MULTIENZYME COMPLEX; NORE1A PROTEIN; SCF BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE; CTNNB1 PROTEIN, HUMAN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEASOME; PROTEIN BINDING; RAS PROTEIN; RASSF5 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBSTRATE COMPLEX; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE RAS; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BETA CATENIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MONOMERIC GTP-BINDING PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RAS PROTEINS; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; SUBSTRATE SPECIFICITY;

EID: 84909951731     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.594283     Document Type: Article

References (54)

1. Malumbres, M., and Barbacid, M. (2003) RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-465
2. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. (1998) Increasing complexity of Ras signaling. Oncogene 17, 1395-1413
3. Pacheco-Pinedo, E. C., and Morrisey, E. E. (2011) Wnt and Kras signaling: dark siblings in lung cancer. Oncotarget 2, 569-574
4. Jang, J. W., Boxer, R. B., and Chodosh, L. A. (2006) Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol. Cell. Biol. 26, 8109-8121
5. Jeong, W. J., Yoon, J., Park, J. C., Lee, S. H., Lee, S. H., Kaduwal, S., Kim, H., Yoon, J. B., and Choi, K. Y. (2012) Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis. Sci. Signal. 5, ra30
6. Kim, S. E., Yoon, J. Y., Jeong, W. J., Jeon, S. H., Park, Y., Yoon, J. B., Park, Y. N., Kim, H., and Choi, K. Y. (2009) H-Ras is degraded by Wnt/β-catenin signaling via β-TrCP-mediated polyubiquitylation. J. Cell Sci. 122, 842-848
7. Saifo, M. S., Rempinski, D. R., Jr., Rustum, Y. M., and Azrak, R. G. (2010) Targeting the oncogenic protein β-catenin to enhance chemotherapy outcome against solid human cancers. Mol. Cancer 9, 310
8. Orford, K., Crockett, C., Jensen, J. P., Weissman, A. M., and Byers, S. W. (1997) Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J. Biol. Chem. 272, 24735-24738
9. Giles, R. H., van Es, J. H., and Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1-24
10. Xu, M. X., Zhao, L., Deng, C., Yang, L., Wang, Y., Guo, T., Li, L., Lin, J., and Zhang, L. (2013) Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the Wnt signaling pathway. Int. J. Oncol.
11. Liu, C., Kato, Y., Zhang, Z., Do, V. M., Yankner, B. A., and He, X. (1999) β-Trcp couples β-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl. Acad. Sci. U.S.A. 96, 6273-6278
12. Karin, M., Cao, Y., Greten, F. R., and Li, Z. W. (2002) NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2, 301-310
13. Richmond, A. (2002) NF-κB, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2, 664-674
14. Mamely, I., van Vugt, M. A., Smits, V. A., Semple, J. I., Lemmens, B., Perrakis, A., Medema, R. H., and Freire, R. (2006) Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr. Biol. 16, 1950-1955
15. Cox, A. D., and Der, C. J. (2003) The dark side of Ras: regulation of apoptosis. Oncogene 22, 8999-9006
16. Donninger, H., Vos, M. D., and Clark, G. J. (2007) The RASSF1A tumor suppressor. J. Cell Sci. 120, 3163-3172
17. Schmidt, L., C. G. (2011) RASSF5 (Ras association (RalGDS/AF-6) domain family member 5). Atlas Genet. Cytogenet. Oncol. Haematol.
18. Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X. F., Seed, B., and Avruch, J. (2002) Identification of a novel Rasregulated proapoptotic pathway. Curr. Biol. 12, 253-265
19. Vos, M. D., Martinez, A., Ellis, C. A., Vallecorsa, T., and Clark, G. J. (2003) The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J. Biol. Chem. 278, 21938-21943
20. van der Weyden, L., and Adams, D. J. (2007) The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim. Biophys. Acta 1776, 58-85
21. Chen, J., Lui, W. O., Vos, M. D., Clark, G. J., Takahashi, M., Schoumans, J., Khoo, S. K., Petillo, D., Lavery, T., Sugimura, J., Astuti, D., Zhang, C., Kagawa, S., Maher, E. R., Larsson, C., Alberts, A. S., Kanayama, H. O., and Teh, B. T. (2003) The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 4, 405-413
22. Kolligs, F. T., Hu, G., Dang, C. V., and Fearon, E. R. (1999) Neoplastic transformation of RK3E by mutant β-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol. Cell. Biol. 19, 5696-5706
23. Clark, G. J., Cox, A. D., Graham, S. M., and Der, C. J. (1995) Biological assays for Ras transformation. Methods Enzymol. 255, 395-412
24. Fiordalisi, J. J., Johnson, R. L., 2nd, Ulkü, A. S., Der, C. J., and Cox, A. D. (2001) Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Methods Enzymol. 332, 3-36
25. Vos, M. D., Ellis, C. A., Elam, C., Ulku, A. S., Taylor, B. J., and Clark, G. J. (2003) RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol. Chem. 278, 28045-28051
26. Schulman, B. A., Carrano, A. C., Jeffrey, P. D., Bowen, Z., Kinnucan, E. R., Finnin, M. S., Elledge, S. J., Harper, J. W., Pagano, M., and Pavletich, N. P. (2000) Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 408, 381-386
27. Ortiz-Vega, S., Khokhlatchev, A., Nedwidek, M., Zhang, X. F., Dammann, R., Pfeifer, G. P., and Avruch, J. (2002) The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 21, 1381-1390
28. Biechele, T. L., Adams, A. M., and Moon, R. T. (2009) Transcription-based reporters of Wnt/β-catenin signaling. Cold Spring Harbor protocols 2009, pdb prot5223
29. Shinmura, K., Tao, H., Nagura, K., Goto, M., Matsuura, S., Mochizuki, T., Suzuki, K., Tanahashi, M., Niwa, H., Ogawa, H., and Sugimura, H. (2011) Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma. Lung Cancer 71, 19-27
30. Baeuerle, P. A. (1998) IκB-NF-κB structures: at the interface of inflammation control. Cell 95, 729-731
31. Espada, J., Pérez-Moreno, M., Braga, V. M., Rodriguez-Viciana, P., and Cano, A. (1999) H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of β-catenin in epidermal keratinocytes. J. Cell Biol. 146, 967-980
32. Kim, D., Rath, O., Kolch, W., and Cho, K. H. (2007) A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene 26, 4571-4579
33. Reuter, C. W., Morgan, M. A., and Bergmann, L. (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96, 1655-1669
34. Aoyama, Y., Avruch, J., and Zhang, X. F. (2004) Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 23, 3426-3433
35. Morin, P. J. (1999) β-Catenin signaling and cancer. BioEssays 21, 1021-1030
36. Horst, D., Chen, J., Morikawa, T., Ogino, S., Kirchner, T., and Shivdasani, R. A. (2012) Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 72, 1547-1556
37. Bos, J. L. (1989) Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689
38. Yaron, A., Hatzubai, A., Davis, M., Lavon, I., Amit, S., Manning, A. M., Andersen, J. S., Mann, M., Mercurio, F., and Ben-Neriah, Y. (1998) Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 396, 590-594
39. Hatakeyama, S., Kitagawa, M., Nakayama, K., Shirane, M., Matsumoto, M., Hattori, K., Higashi, H., Nakano, H., Okumura, K., Onoé, K., Good, R. A., and Nakayama, K. (1999) Ubiquitin-dependent degradation of IκBα is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc. Natl. Acad. Sci. U.S.A. 96, 3859-3863
40. Orian, A., Gonen, H., Bercovich, B., Fajerman, I., Eytan, E., Israël, A., Mercurio, F., Iwai, K., Schwartz, A. L., and Ciechanover, A. (2000) SCF(β)(-TrCP) ubiquitin ligase-mediated processing of NF-κB p105 requires phosphorylation of its C-terminus by IκB kinase. EMBO J. 19, 2580-2591
41. Huntzicker, E. G., Estay, I. S., Zhen, H., Lokteva, L. A., Jackson, P. K., and Oro, A. E. (2006) Dual degradation signals control Gli protein stability and tumor formation. Genes Dev. 20, 276-281
42. Pan, Y., and Wang, B. (2007) A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein degradation by the proteasome. J. Biol. Chem. 282, 10846-10852
43. Guardavaccaro, D., Frescas, D., Dorrello, N. V., Peschiaroli, A., Multani, A. S., Cardozo, T., Lasorella, A., Iavarone, A., Chang, S., Hernando, E., and Pagano, M. (2008) Control of chromosome stability by the β-TrCP-REST-Mad2 axis. Nature 452, 365-369
44. Westbrook, T. F., Hu, G., Ang, X. L., Mulligan, P., Pavlova, N. N., Liang, A., Leng, Y., Maehr, R., Shi, Y., Harper, J. W., and Elledge, S. J. (2008) SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452, 370-374
45. Lassot, I., Ségéral, E., Berlioz-Torrent, C., Durand, H., Groussin, L., Hai, T., Benarous, R., and Margottin-Goguet, F. (2001) ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(βTrCP) ubiquitin ligase. Mol. Cell. Biol. 21, 2192-2202
46. Busino, L., Donzelli, M., Chiesa, M., Guardavaccaro, D., Ganoth, D., Dorrello, N. V., Hershko, A., Pagano, M., and Draetta, G. F. (2003) Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 426, 87-91
47. Kanemori, Y., Uto, K., and Sagata, N. (2005) β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl. Acad. Sci. U.S.A. 102, 6279-6284
48. Peschiaroli, A., Dorrello, N. V., Guardavaccaro, D., Venere, M., Halazonetis, T., Sherman, N. E., and Pagano, M. (2006) SCFβTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol. Cell 23, 319-329
49. Mailand, N., Bekker-Jensen, S., Bartek, J., and Lukas, J. (2006) Destruction of Claspin by SCFβTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol. Cell 23, 307-318
50. Estrabaud, E., Lassot, I., Blot, G., Le Rouzic, E., Tanchou, V., Quemeneur, E., Daviet, L., Margottin-Goguet, F., and Benarous, R. (2007) RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of β-catenin by interacting with βTrCP. Cancer Res. 67, 1054-1061
51. Zhao, B., Lei, Q. Y., and Guan, K. L. (2008) The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr. Opin. Cell Biol. 20, 638-646
52. Zhao, B., Li, L., Lei, Q., and Guan, K. L. (2010) The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24, 862-874
53. Liu, C. Y., Zha, Z. Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., Chan, S. W., Lim, C. J., Hong, W., Zhao, S., Xiong, Y., Lei, Q. Y., and Guan, K. L. (2010) The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. J. Biol. Chem. 285, 37159-37169
54. Konsavage, W. M., Jr., and Yochum, G. S. (2013) Intersection of Hippo/ YAP and Wnt/β-catenin signaling pathways. Acta Biochim. Biophys. Sinica 45, 71-79